Literature DB >> 18057309

Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients.

Alfred K Cheung1, Tom Greene, John K Leypoldt, Guofen Yan, Michael Allon, James Delmez, Andrew S Levey, Nathan W Levin, Michael V Rocco, Gerald Schulman, Garabed Eknoyan.   

Abstract

BACKGROUND AND OBJECTIVES: Secondary analysis of the Hemodialysis Study showed that serum beta(2)-microglobulin levels predicted all-cause mortality and that high-flux dialysis was associated with decreased cardiac deaths in hemodialysis patients. This study examined the association of serum beta(2)-microglobulin levels and dialyzer beta(2)-microglobulin kinetics with the two most common causes of deaths: Cardiac and infectious diseases. Cox regression analyses were performed to relate cardiac or infectious deaths to cumulative mean follow-up predialysis serum beta(2)-microglobulin levels while controlling for baseline demographics, comorbidity, residual kidney function, and dialysis-related variables.
RESULTS: The cohort of 1813 patients experienced 180 infectious deaths and 315 cardiac deaths. The adjusted hazard ratio for infectious death was 1.21 (95% confidence interval 1.07 to 1.37) per 10-mg/L increase in beta(2)-microglobulin. This association was independent of the prestudy years on dialysis. In contrast, the association between serum beta(2)-microglobulin level and cardiac death was not statistically significant. In similar regression models, higher cumulative mean Kt/V of beta(2)-microglobulin was not significantly associated with either infectious or cardiac mortality in the full cohort but exhibited trends suggesting an association with lower infectious mortality (relative risk 0.93; 95% confidence interval 0.86 to 1.01, for each 0.1-U increase in beta(2)-microglobulin Kt/V) and lower cardiac mortality (relative risk 0.93; 95% confidence interval 0.87 to 1.00) in the subgroup with >3.7 prestudy years of dialysis.
CONCLUSIONS: These results generally support the notion that middle molecules are associated with systemic toxicity and that their accumulation predisposes dialysis patients to infectious deaths, independent of the duration of maintenance dialysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057309      PMCID: PMC2390979          DOI: 10.2215/CJN.02340607

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  25 in total

1.  Mechanisms for the formation of glycoxidation products in end-stage renal disease.

Authors:  M F Weiss; P Erhard; F A Kader-Attia; Y C Wu; P B Deoreo; A Araki; M A Glomb; V M Monnier
Journal:  Kidney Int       Date:  2000-06       Impact factor: 10.612

Review 2.  Review on uremic toxins: classification, concentration, and interindividual variability.

Authors:  Raymond Vanholder; Rita De Smet; Griet Glorieux; Angel Argilés; Ulrich Baurmeister; Philippe Brunet; William Clark; Gerald Cohen; Peter Paul De Deyn; Reinhold Deppisch; Beatrice Descamps-Latscha; Thomas Henle; Achim Jörres; Horst Dieter Lemke; Ziad A Massy; Jutta Passlick-Deetjen; Mariano Rodriguez; Bernd Stegmayr; Peter Stenvinkel; Ciro Tetta; Christoph Wanner; Walter Zidek
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

3.  Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study.

Authors:  Michael Allon; Thomas A Depner; Milena Radeva; James Bailey; Srinivasan Beddhu; David Butterly; Daniel W Coyne; Jennifer J Gassman; Allen M Kaufman; George A Kaysen; Julia A Lewis; Steve J Schwab
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

4.  Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells.

Authors:  W H Hörl; M Haag-Weber; A Georgopoulos; L H Block
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

5.  Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study.

Authors:  Alfred K Cheung; Michael V Rocco; Guofen Yan; John K Leypoldt; Nathan W Levin; Tom Greene; Lawrence Agodoa; James Bailey; Gerald J Beck; William Clark; Andrew S Levey; Daniel B Ornt; Gerald Schulman; Steven Schwab; Brendan Teehan; Garabed Eknoyan
Journal:  J Am Soc Nephrol       Date:  2005-12-28       Impact factor: 10.121

6.  Design and statistical issues of the hemodialysis (HEMO) study.

Authors:  T Greene; G J Beck; J J Gassman; F A Gotch; J W Kusek; A S Levey; N W Levin; G Schulman; G Eknoyan
Journal:  Control Clin Trials       Date:  2000-10

7.  Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study.

Authors:  Alfred K Cheung; Mark J Sarnak; Guofen Yan; Michael Berkoben; Robert Heyka; Allen Kaufman; Julia Lewis; Michael Rocco; Robert Toto; David Windus; Daniel Ornt; Andrew S Levey
Journal:  Kidney Int       Date:  2004-06       Impact factor: 10.612

8.  Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study.

Authors:  Alfred K Cheung; Nathan W Levin; Tom Greene; Lawrence Agodoa; James Bailey; Gerald Beck; William Clark; Andrew S Levey; John K Leypoldt; Daniel B Ornt; Michael V Rocco; Gerald Schulman; Steve Schwab; Brendan Teehan; Garabed Eknoyan
Journal:  J Am Soc Nephrol       Date:  2003-12       Impact factor: 10.121

9.  Advanced glycosylation end products in patients with diabetic nephropathy.

Authors:  Z Makita; S Radoff; E J Rayfield; Z Yang; E Skolnik; V Delaney; E A Friedman; A Cerami; H Vlassara
Journal:  N Engl J Med       Date:  1991-09-19       Impact factor: 91.245

Review 10.  Biochemical and clinical evidence for uremic toxicity.

Authors:  Tony Bouré; Raymond Vanholder
Journal:  Artif Organs       Date:  2004-03       Impact factor: 3.094

View more
  24 in total

Review 1.  Role of β2-microglobulin in uremic patients may be greater than originally suspected.

Authors:  Aysegul Zumrutdal
Journal:  World J Nephrol       Date:  2015-02-06

2.  The impact of membrane permeability and dialysate purity on cardiovascular outcomes.

Authors:  Gulay Asci; Huseyin Tz; Mehmet Ozkahya; Soner Duman; Meltem Sezis Demirci; Mustafa Cirit; Savas Sipahi; Hamad Dheir; Devrim Bozkurt; Fatih Kircelli; Ebru Sevinc Ok; Sinan Erten; Muhittin Ertilav; Timur Kose; Ali Basci; Jochen G Raimann; Nathan W Levin; Ercan Ok
Journal:  J Am Soc Nephrol       Date:  2013-04-25       Impact factor: 10.121

Review 3.  An update on uremic toxins.

Authors:  N Neirynck; R Vanholder; E Schepers; S Eloot; A Pletinck; G Glorieux
Journal:  Int Urol Nephrol       Date:  2012-08-15       Impact factor: 2.370

4.  Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial.

Authors:  M C Foster; D E Weiner; A G Bostom; M A Carpenter; L A Inker; P Jarolim; A A Joseph; J W Kusek; T Pesavento; M A Pfeffer; M Rao; S D Solomon; A S Levey
Journal:  Am J Transplant       Date:  2017-03-30       Impact factor: 8.086

5.  Role of residual kidney function and convective volume on change in beta2-microglobulin levels in hemodiafiltration patients.

Authors:  E Lars Penne; Neelke C van der Weerd; Peter J Blankestijn; Marinus A van den Dorpel; Muriel P C Grooteman; Menso J Nubé; Piet M Ter Wee; Renée Lévesque; Michiel L Bots
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-12       Impact factor: 8.237

6.  Effect of membrane permeability on survival of hemodialysis patients.

Authors:  Francesco Locatelli; Alejandro Martin-Malo; Thierry Hannedouche; Alfredo Loureiro; Menelaos Papadimitriou; Volker Wizemann; Stefan H Jacobson; Stanislaw Czekalski; Claudio Ronco; Raymond Vanholder
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

7.  Should we still focus that much on cardiovascular mortality in end stage renal disease patients? The CONvective TRAnsport STudy.

Authors:  Claire H den Hoedt; Michiel L Bots; Muriel P C Grooteman; Albert H A Mazairac; E Lars Penne; Neelke C van der Weerd; Piet M Ter Wee; Menso J Nubé; Renée Levesque; Peter J Blankestijn; Marinus A van den Dorpel
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

Review 8.  Prognostic effect of high-flux hemodialysis in patients with chronic kidney disease.

Authors:  X Li; H Xu; X C Xiao; S L Deng; W Wang; R Tang
Journal:  Braz J Med Biol Res       Date:  2015-11-27       Impact factor: 2.590

Review 9.  β2-Microglobulin-mediated signaling as a target for cancer therapy.

Authors:  Takeo Nomura; Wen-Chin Huang; Haiyen E Zhau; Sajni Josson; Hiromitsu Mimata; Leland W K Chung
Journal:  Anticancer Agents Med Chem       Date:  2014-03       Impact factor: 2.505

10.  Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients?

Authors:  Sunny Eloot; Wim Van Biesen; Griet Glorieux; Nathalie Neirynck; Annemieke Dhondt; Raymond Vanholder
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.